Vaccine Manufacturing and Innovation Centre launched during the pandemic as a not-for-profit company that would combine research and manufacturing under one roof. In 2022, the £200m government-funded centre was sold to a private pharmaceutical company. Across the Channel, Europe – which found itself in hot competition with the UK and US – appears to be much more proactive.